Chelsea Therapeutics, Inc. to Present Phase II Intradialytic Hypotension Data in Late Breaking Clinical Trials Session At World Congress of Nephrology 2009

CHARLOTTE, N.C., May 21, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that data from the Company’s Phase II trial of Droxidopa in intradialytic hypotension (IDH) will be presented at the World Congress of Nephrology 2009 in Milan, Italy on Sunday, May 24 at 10:30 AM local time.